Antibiotic therapy-induced collateral damage: IgA takes center stage in pulmonary host defense

The Journal of Clinical Investigation
Juergen LohmeyerSusanne Herold

Abstract

The use of broad-spectrum antibiotics in empirical antimicrobial therapy is a lifesaving strategy for patients in intensive care. At the same time, antibiotics dramatically increase the risk for nosocomial infections, such as hospital‑acquired pneumonia caused by Pseudomonas aeruginosa, and other antibiotic-resistant bacteria. In this issue of the JCI, Robak and colleagues identified a mechanism by which depletion of resident gut and lung microbiota by antibiotic treatment results in secondary IgA deficiency and impaired anti-P. aeruginosa host defense. Impaired defenses could be improved by substitution of polyclonal IgA via the intranasal route in a mouse model of pneumonia. Importantly, antibiotic treatment caused lung IgA deficiency that involved reduced TLR-dependent production of a proliferation-inducing ligand (APRIL) and B cell-activating factor (BAFF) in intensive care unit patients. These patients might therefore benefit from future strategies to increase pulmonary IgA levels.

References

Aug 3, 2002·Nature Immunology·Mikhail B LitinskiyAndrea Cerutti
Dec 3, 2009·JAMA : the Journal of the American Medical Association·Jean-Louis VincentUNKNOWN EPIC II Group of Investigators
Jan 19, 2010·Nature Medicine·Thomas B ClarkeJeffrey N Weiser
Mar 16, 2011·Proceedings of the National Academy of Sciences of the United States of America·Takeshi IchinoheAkiko Iwasaki
Oct 30, 2012·Nature Reviews. Immunology·Oliver Pabst
Nov 23, 2012·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·P ZarbUNKNOWN Hospital Contact Points for the ECDC pilot point prevalence survey
Jul 17, 2013·American Journal of Respiratory and Critical Care Medicine·Yuichiro ShindoYoshinori Hasegawa
Oct 8, 2013·Nature Reviews. Immunology·Charlie G Buffie, Eric G Pamer
Jul 8, 2016·Nature·Kenya Honda, Dan R Littman
Aug 2, 2016·Cell Host & Microbe·Myunghoo KimChang H Kim
Feb 6, 2018·Annual Review of Immunology·Andrew J MacphersonStephanie C Ganal-Vonarburg
May 18, 2018·The Journal of Clinical Investigation·Oliver H RobakBastian Opitz

❮ Previous
Next ❯

Citations

May 3, 2019·American Journal of Respiratory and Critical Care Medicine·Michael S NiedermanNeil W Schluger
Jan 24, 2021·Molecular and Cellular Biochemistry·Suresh C Tyagi, Mahavir Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Fernando Bellissimo-RodriguesRoberto Martinez
Enfermedades infecciosas y microbiología clínica
Emili DíazJordi Vallés
© 2022 Meta ULC. All rights reserved